文献速递系统性红斑狼疮

系统性红斑狼疮患者长期结局的模型构建

Modelling long-term outcomes for patients with systemic lupus erythematosus.
PubMed 文献 · Semin Arthritis Rheum · 2024-07-02

基于多伦多狼疮队列1997至2020年1255例患者数据,建立广义线性模型与参数加速失效时间生存模型,发现疾病活动度和糖皮质激素用量是器官损害与死亡的重要预测因素,提示需减少疾病活动与激素使用以改善长期结局。

要点

  • 队列1255例,89%女性,65%白人,平均随访10.5年,中位生存约35年。
  • 年均SLEDAI-2K与平均GC剂量可预测SLEDAI-2K变化、GC使用/剂量及复发。
  • 调整后平均SLEDAI-2K与GC剂量至少预测12个器官系统中9个的损害及死亡。

核心结论

  • 疾病活动度和糖皮质激素使用是 predominantly 中重度SLE患者器官损害与死亡的重要预测因素。
  • 研究加深了对SLE自然史的理解,并强调需要减少疾病活动度和GC使用以改善长期结局的新治疗方法。

研究设计与样本

  • 基于多伦多狼疮队列(TLC)前瞻性收集数据(1997—2020年)的纵向回顾性分析。
  • 纳入1255例SLE患者,89%为女性,65%为白人,平均随访10.5年。
  • 采用广义线性模型和参数加速失效时间生存模型,经双变量及多变量回归筛选临床和统计学显著协变量以确定最佳拟合模型。

主要发现

  • 首次就诊时51%患者有中重度疾病活动(SLEDAI-2K评分≥6)。
  • 诊断后多年平均器官损害评分逐渐增加。
  • 队列中位生存期约为自研究入组起35年。
  • 在GLM模型中,SLEDAI-2K年均值和平均GC剂量是预测SLEDAI-2K变化、GC使用/剂量和复发(任何/发生率)的关键因素。
  • 调整后平均SLEDAI-2K和GC剂量共同被证明是至少12个所考虑器官系统中9个的死亡和损害的预测因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New treatments for systemic lupus erythematosus (SLE) aim to improve tolerability and disease activity control over standard of care (SoC) treatment. SoC typically includes daily glucocorticoid (GC) which carries a risk of organ damage over time. This study sought to develop natural history models to identify predictors of long-term outcomes with current SoC SLE treatment. METHODS: Generalized linear and parametric accelerated failure time survival models (GLM) and parametric accelerated failure time (AFT) survival models were designed to identify predictors of disease activity, flare rate, GC use, organ damage, and mortality beyond the first year of treatment in patients with SLE. Models were run using a longitudinal retrospective analysis of prospectively collected Toronto Lupus Cohort (TLC) study data, collected between 1997 and 2020. Covariates of clinical and statistical significance were selected by bivariate- then multi-variate regression to find the model of best fit. FINDINGS: Of the 1255 subjects included, 89 % were female 89 % and 65 % Caucasian. Mean follow-up was 10·5 years. At first visit, 51 % of patients had moderate-to-severe disease activity (SLEDAI-2 K score ≥ 6). Mean organ damage scores gradually increased over the years following diagnosis. Median survival of the cohort was ∼35 years from study entry. In the GLM models, SLEDAI-2 K yearly average, and average GC dose were key for predicting change in SLEDAI-2 K, GC use/ dose, and flare (any/rate). Together, adjusted mean SLEDAI-2 K and GC dose were shown to be predictors of mortality and damage in at least 9 of 12 organ systems considered. INTERPRETATION: These comprehensive, longitudinal, predictive models show that disease activity and GC use are significant predictors of organ damage and mortality in a patient population with predominantly moderate to severe SLE. This deepens understanding of SLE natural history and underscores the need for new treatment approaches that reduce disease activity and GC use with an aim to improve long-term SLE outcomes. FUNDING: This study was funded by AstraZeneca.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Touma Z, Kayaniyil S, Parackal A, et al. Modelling long-term outcomes for patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2024. PMID: 39029291. doi:10.1016/j.semarthrit.2024.152507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。